Press Releases / Notices

The company’s press releases sometimes carry information on pharmaceutical drugs and products in the pipeline. Under no circumstances is such information provided to promote or advertise these products or offer medical advice.

NEWS 2026

November 16, 2026 Pharmaceuticals
  • SHARE
  • facebook
  • X

Antineoplastic Agent “Jaypirca® 50 mg and 100 mg tablets” Approved for Expanded Indication in Chronic Lymphocytic Leukemia – Now Available as a First-Line Treatment for Previously Untreated Patients –

Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; Headquarters: Kyoto; President: Toru Nakai) and Eli Lilly Japan K.K. (Eli Lilly Japan; Headquarters: Kobe; President and Representative Director: Karla Alcazar) announced today, November 16, 2026, that Eli Lilly Japan has received approval in Japan for an expanded indication of the antineoplastic agent “Jaypirca® 50 mg and 100 mg tablets” (generic name: pirtobrutinib; hereinafter referred to as “Jaypirca”) for “chronic lymphocytic leukemia (including small lymphocytic lymphoma).”

Jaypirca is a Bruton tyrosine kinase (BTK) inhibitor that binds reversibly and noncovalently to BTK. BTK is a target molecule recognized in many B-cell lymphomas and leukemias, including chronic lym-phocytic leukemia and mantle cell lymphoma.

This approval is based on the efficacy and safety results of two global Phase 3 studies, the BRUIN-CLL-313 study and the BRUIN-CLL-314 study. The BRUIN-CLL-313 study compared pirtobrutinib 200 mg orally once daily as monotherapy with bendamustine plus rituximab (bendamustine + rituximab arm: BR Arm) in 282 patients (including 12 Japanese patients) with untreated chronic lymphocytic leukemia and small lymphocytic lymphoma. For the primary endpoint of progression-free survival by central assessment, a statistically significant extension was observed in the pirtobrutinib arm com-pared with the BR Arm. The BRUIN-CLL-314 study compared pirtobrutinib 200 mg orally once daily as monotherapy (Pirtobrutinib Arm) with ibrutinib 420 mg orally once daily as monotherapy (Ibrutinib Arm) in 662 patients (including 3 Japanese patients) with chronic lymphocytic leukemia and small lymphocytic lymphoma who were untreated or had received prior therapy other than BTK inhibitors. The primary endpoint was overall response rate by central assessment.
Based on the alliance agreement concluded in March 2024, Eli Lilly Japan will be responsible for sup-ply of Jaypirca in Japan, while Nippon Shinyaku will be responsible for distribution and sales, as well as information provision activities.

Summary of Product Information
Brand nameJaypirca® 50 mg Tablets, Jaypirca® 100 mg Tablets
Generic namePirtobrutinib
Indications

① Relapsed or refractory mantle cell lymphoma resistant or intolerant to other BTK inhibitors

② Chronic lymphocytic leukemia (including small lymphocytic lymphoma)

Dosage and administrationIn adult patients, the recommended dosage is pirtobrutinib 200 mg orally once daily. Reduce the dose accordingly based on the patient’s condition.
Date of marketing approval June 24, 2024
Date of NHI price listingAugust 15, 2024
Launch dateAugust 21, 2024
NHI price

Jaypirca® 50 mg Tablets   Per 50 mg tablet    JPY 10,201.00 

Jaypirca® 100 mg Tablets Per 100 mg tablet  JPY 19,465.80 

ManufacturerEli Lilly Japan K.K.
DistributorNippon Shinyaku Co., Ltd. 

Product images

                  Jaypirca® 50 mg Tablets                                                                      Jaypirca® 100 mg Tablets

Global Phase 3 Randomized Controlled Study (BRUIN-CLL-313 Study)
The BRUIN-CLL-313 study compared pirtobrutinib 200 mg orally once daily as monotherapy (Pirto-brutinib Arm) with bendamustine plus rituximab※2 (BR Arm) in 282 patients (including 12 Japanese patients) with untreated chronic lymphocytic leukemia and small lymphocytic lymphoma※1. Progres-sion-free survival by central assessment, the primary endpoint, is shown in the table below; a statisti-cally significant extension was observed in the Pirtobrutinib Arm compared with the BR Arm.
※1) Patients without chromosome 17p deletion were included
※2) One cycle is 28 days. Bendamustine hydrochloride 90 mg/m2 was administered intravenously on Days 1 and 2 of Cycles 1–6. Rituximab (genetic recombination) 375 mg/m2 was administered on Day 1 of Cycle 1, followed by 500 mg/m2 intravenously on Day 1 of Cycles 2–6

Results of the Global Phase 3 Randomized Controlled Study (BRUIN-CLL-313 Study)


Adverse drug reactions were observed in 83 (59.3%) of the 140 patients (including 4 Japanese pa-tients) in the Pirtobrutinib Arm in the safety analysis population. The most common adverse drug re-actions in the Pirtobrutinib Arm were neutropenia (10.7%), hypertension (5.0%), urinary tract infection (5.0%), contusion (4.3%), and petechiae (4.3%). 

Global Phase 3 Study (BRUIN-CLL-314 Study)
The BRUIN-CLL-314 study was an open-label, randomized Phase 3 study comparing pirtobrutinib 200 mg orally once daily as monotherapy (Pirtobrutinib Arm) with ibrutinib 420 mg orally once daily as monotherapy (Ibrutinib Arm) in 662 patients (including 3 Japanese patients) with chronic lymphocytic leukemia and small lymphocytic lymphoma who were untreated or had received prior therapy other than BTK inhibitors※3. The primary endpoint, overall response rate (ORR) by central assessment, is shown in the table below.
※3) Patients previously treated with BTK inhibitors were excluded from enrollment

Results of the Global Phase 3 Randomized Controlled Study (BRUIN-CLL-314 Study)


Adverse drug reactions were observed in 254 (77.0%) of the 330 patients (including 3 Japanese pa-tients) in the Pirtobrutinib Arm in the safety analysis population. The most common adverse drug re-actions in the Pirtobrutinib Arm were neutropenia (20.0%), anemia (9.7%), contusion (8.5%), neutro-phil count decreased (6.7%), and pneumonia (6.7%). 

About Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)
CLL and SLL are both tumors that arise from lymphocytes, a type of white blood cell, and are slowly progressing diseasesi,ii. In Japan, CLL and SLL are rare diseases, and the total numbers of patients are estimated at 7,000 and 4,000, respectivelyiii. CLL and SLL share the same pathological features and immunophenotype but differ in where the cancer cells are located in the bodyi. In CLL, the cancer cells are found in the blood, whereas in SLL, the cancer cells are found in the lymph nodesi.
i. Mukkamalla SKR, Taneja A, Malipeddi D, et al. Chronic Lymphocytic Leukemia. [Updated 2023 Feb 18]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan. Available from: https://www.ncbi.nlm.nih.gov/books/NBK470433/ 
ii. The Leukemia and Lymphoma Society. NHL Subtypes. Access here: https://bloodcancerunited.org/blood-cancer/lymphoma/non-hodgkin-lymphoma-nhl. Accessed on October 25, 2023.
iii. Government statistics: Patient Survey, FY2023 (Reiwa 5)


About Nippon Shinyaku  
Based on Nippon Shinyaku’s business philosophy, “Helping people lead healthier, happier lives,” we  aim to be an organization trusted by the community through creating unique medicines that will bring  hope to patients and families suffering from illness. Please visit our website (https://www.nippon-shinyaku.co.jp/english/) for products or detailed information.

About Eli Lilly Japan 
Eli Lilly Japan is the Japanese subsidiary of Eli Lilly and Company based in the United States.We have been developing and supplying world-class, innovative medicines by uniting caring with discovery for 50 years to help patients in Japan achieve healthier and more fulfilling lives. We currently contribute to Japanese medicine in multiple areas, including cancer, diabetes, Alzheimer's disease and other central nervous system diseases, as well as autoimmune diseases, etc. For more details, please visit our website. 

Contact
Public Relations & Investor Relations Dept., Nippon Shinyaku Co., Ltd.
e_mail_kouhou@po.nippon-shinyaku.co.jp